84% in mice is not a human breakthrough
Immorta Bio's mouse result is a real preclinical signal for senolytics, not proof that a two-part anti-aging therapy now works in humans.
84% lifespan extension. In mice.
That is the part worth reading twice. Immorta Bio says its SenoVax + StemCellRevivify combination pushed median lifespan up by as much as 84% overall, and by 100% in a doxorubicin-induced model. That is not trivial. It is also not a license to start shouting about "curing aging" like a man who has just discovered a podcast microphone.
What this does prove
A combination approach aimed at senescent cells plus regeneration can produce a large preclinical effect in mouse models. The company also reports better physical performance and shifts in aging-related biomarkers. Fine. That is a signal.
What this does not prove
It does not prove human lifespan extension. It does not prove the effect survives outside these models. It does not prove the stem-cell part is the magic ingredient, or that the synergy claim will hold up once independent data arrive. Conference presentations are not the same thing as durable clinical evidence. Annoying, but true.
If you want the useful angle inside Eternal Search, start with senolytics. That is the cleaner half of the story: one part of the combo is explicitly meant to eliminate senescent cells. The linked page gives you the term itself, so you can inspect the concept before getting carried away by a very large mouse number.
This item is fresh, concrete, and easy to overhype, which makes it a good Eternal Search target. The linked Senolytics glossary page is the right angle because one named component, SenoVax, is explicitly described as eliminating senescent cells, while the press-release-sized lifespan claim still needs to be separated from any claim about humans.